SMYD3 and plasma cell myeloma: The epigenetic studies on herbal medicine for myeloma were mainly conducted with triptolide by Wen et al. In 2010, using multiple myeloma cell line U266, it was found that triptolide dose-dependently reduced the genome-wide H3K4me3, H3K27me3, and H3K36me3, while also inhibiting SMYD3, EZH2 and nuclear receptor binding SET domain protein 1 (NSD1) expression [53].